ABCG2 and non-small cell lung carcinoma: Consequently, individuals with NSCLC harboring EGFR L858R mutation may also be better candidates for ABCP therapy, which is suggested for the first time in this study. To validate the efficacy of ABCP combination therapy in patients with EGFR-positive non-squamous NSCLC, especially those with EGFR L858R mutation, a phase 3 study with a larger cohort is warranted.